QoL · children (12 or over) and adults with cystic fibrosis and lung infection
1 finding from 1 review
Sputum microbiology · children (12 or over) and adults with cystic fibrosis and lung infection
1 finding from 1 review
Inflammatory markers · children (12 or over) and adults with cystic fibrosis and lung infection
1 finding from 1 review
Clearance or reduction of antibody titres (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
Benznidazole may leads to higher clearance or reduction of antibody titres (N) (a) at 12 months (b)… compared with placebo (low certainty).
1 finding from 1 review
Clearance or reduction of antibody titres (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
It is very uncertain whether nifurtimox changes clearance or reduction of antibody titres (N) compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Antibody production: number of participants developing IgG antibodies · adults and children with mucopolysaccharidosis I
It is very uncertain whether the intervention changes antibody production: number of participants developing IgG antibodies (very low certainty).
1 finding from 1 review
Antibody response (geometric mean titre) · 9‐ to 14‐year‐old females and males
1 finding from 1 review
Antibody response (immunogenicity) · 9‐ to 15‐year‐old females
Two doses of HPV vaccine probably leads to lower antibody response (immunogenicity) compared with three doses of HPV vaccine (moderate certainty).
1 finding from 1 review
Acute rejection, steroid resistant/antibody treated As reported in the articles · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) leads to lower acute rejection, steroid resistant/antibody treated As reported in… compared with azathioprine (AZA) (high certainty).
1 finding from 1 review
Erythrocyte alloantibody formation Laboratory assessment · women with postpartum iron deficiency anaemia
It is very uncertain whether red blood cell transfusion changes erythrocyte alloantibody formation Laboratory assessment compared with non‐transfusion (Comparison 2) (very low certainty).
1 finding from 1 review
Hepatitis B antibody titre (IgG) · people living with HIV
1 finding from 1 review
Immunogenicity: Adequate antibody response (NT ≥1:10), · adults with HIV infection
Immunologic response to YF vaccine in HIV‐infected adults before HIV… may leads to lower immunogenicity: Adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (low certainty).
1 finding from 1 review
Immunogenicity: Adequate antibody response (NT ≥1:10), · Children with HIV infection
It is very uncertain whether immunologic response to YF vaccine in HIV‐infected children changes adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (very low certainty).
1 finding from 1 review
Immunogenicity: Adequate antibody response (NT ≥1:10), · adults with HIV infection
It is very uncertain whether immunologic response to YF vaccine in HIV‐infected adults changes immunogenicity: Adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (very low certainty).
1 finding from 1 review
Duration: Adequate antibody response (NT ≥1:10), · adults with HIV infection
It is very uncertain whether immunologic response to YF vaccine in HIV‐infected adults changes duration: Adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (very low certainty).
1 finding from 1 review
Intervention not reported
HCV antibody vs. placebo · patients undergoing liver transplantation for chronic hepatitis C viral infection.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
HCV antibody vs. placebo · patients undergoing liver transplantation for chronic hepatitis C viral infection.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality Mortality at latest · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in mortality Mortality at latest compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Acute rejection Acute rejection grade 3A or more verified by biopsy · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Infection Number of participants diagnosed with infection · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in infection Number of participants diagnosed with infection compared with monoclonal antibody induction (low certainty).
1 finding from 1 review